Home › Ovarian Epithelial Carcinoma › NCT07905677
Phase 1 Study of VT-101 in Advanced Ovarian Cancer
A Phase 1 Dose-Finding, Safety, and Preliminary Clinical Activity Study of VT-101 in Advanced Ovarian Cancer
Who can join
Ages 18 to 99 · Women
Full eligibility criteria
ELIGIBILITY CRITERIA Inclusion Criteria: * Female participant * Age ≥ 18 years * Histologically confirmed advanced, recurrent, or relapsed epithelial ovarian cancer * Has received prior standard therapy for ovarian cancer, OR has refused standard therapy, OR is intolerant to standard therapy, OR is not eligible for standard therapy * ECOG Performance Status of 0, 1, or 2 * Adequate bone marrow, liver, and kidney function as defined by the protocol * Able to comply with study procedures and provide informed consent * For women of childbearing potential: agrees to use protocol-required contraception and meets pregnancy testing requirements Exclusion Criteria (high-level): * Does not meet the inclusion criteria * Medical conditions or laboratory abnormalities that would make study participation unsafe * Other protocol-defined exclusions as determined by the investigator Sex: • Female only Age: * 18 years and older * No upper age limit specified Healthy Volunteers: * No * Healthy volunteers are not eligible * Participants must have advanced, recurrent, or relapsed epithelial ovarian cancer
About the study
This Phase 1, open-label study will evaluate VT-101, an investigational small-molecule therapy, in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer. The primary objectives are to assess the safety, tolerability, and pharmacokinetic profile of VT-101 and to identify a recommended dose for further study. Secondary and exploratory objectives include evaluation of preliminary antitumor activity and characterization of treatment-related effects in participants with limited standard treatment options.
What is being tested
- VT-101 (drug)
Sponsor: Michael J. Goodheart · Participants: 22 · Started: Oct 26, 2026
Contact the study team
- Michael Goodheart, MD · Phone: +1 319 356 2015
Official record on ClinicalTrials.gov — NCT07905677
Locations in the U.S.
| Iowa | University of Iowa Health Care, Iowa City |
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.